Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 92 for:    Recruiting Studies | fecal microbiota transplantation

Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03214289
Recruitment Status : Recruiting
First Posted : July 11, 2017
Last Update Posted : April 9, 2018
Sponsor:
Information provided by (Responsible Party):
Dr. Shouval Roni, Sheba Medical Center

Brief Summary:

The investigators hypothesize that perturbations in the intestinal microbiota following allogeneic hematopoietic stem cell transplantation (HSCT) are essential for the development and propagation of acute graft-versus-host disease. Therefore, modification of HSCT recipients' gut microbiota using fecal transplantation from a healthy donor could be used to treat gut acute GVHD.

The study evaluates safety and feasibility of fecal microbiota transplantation with frozen capsules from healthy donors for the treatment of steroid resistant or steroid dependent acute graft-versus-host disease of the gut.


Condition or disease Intervention/treatment Phase
Stem Cell Transplant Complications Graft Versus Host Disease, Acute Fecal Microbiota Transplantation Biological: Fecal Microbiota Transplantation Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fecal Microbiota Transplantation for Treatment of Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease- a Pilot Study
Actual Study Start Date : July 12, 2017
Estimated Primary Completion Date : July 20, 2019
Estimated Study Completion Date : December 20, 2019


Arm Intervention/treatment
Experimental: Fecal Microbiota Transplantation (FMT)

Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.

Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.

Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected.

Biological: Fecal Microbiota Transplantation
Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.




Primary Outcome Measures :
  1. Serious adverse events [ Time Frame: 28 days following FMT. ]
    Participants will be evaluated for serious adverse events (SAEs) relating to FMT occurring within 28 days following transplantation. SAEs are defined as any adverse experience occurring during or after FMT that results in any of the following outcomes: death, life-threatening experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity or an important medical event events


Secondary Outcome Measures :
  1. Non-serious adverse events [ Time Frame: 28 days following FMT. ]
    Participants will be evaluated for non-serious adverse events relating to FMT within 28 days following transplantation. Non-serious adverse events are defined as diarrhea, nausea and vomiting, fatigue and malaise, headache, and distension/bloating/abdominal discomfort/pain

  2. Gut acute Graft-versus-Host Disease (aGvHD) response. [ Time Frame: up to 28 days following FMT. ]

    Participants will be evaluated on days 7 and 28 following transplantation for response to therapy.

    Response criteria for steroid-resistant patients is as follows:

    • Complete response: resolution of all gastrointestinal signs and symptoms
    • Partial response: decrease in severity of gut GVHD by at least one stage
    • Progression: Progressive worsening of gut GVHD
    • No change: No significant change in gut GVHD

    Response criteria for steroid-dependent patients is as follows:

    • Complete response: reduction of the steroid dose to 5 mg or less of prednisone (or a steroid equivalent) per day.
    • Partial response: a reduction of ≥40% in the dose of steroid
    • Progression: an increase of >=10% in the steroid dose
    • No change: any other option

  3. aGvHD severity [ Time Frame: up to 28 days following FMT. ]

    Participants will be evaluated on days 7 and 28 following transplantation for severity of aGvHD.

    aGVHD severity is graded by the International Bone Marrow Transplant Registry Severity Index grading system


  4. Reduction in the dose of steroids. [ Time Frame: up to 28 days following FMT. ]
    The dose of methylprednisolone, or an equivalent GCS, will be evaluated on day 7, and 28. The change in the dose at day 28, adjusted to the type of GCS used.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults (ages 18 to 75 years) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and developed gut acute Graft-versus-Host Disease (aGvHD).
  • Participants have steroid-resistant or steroid-dependent gut aGvHD.
  • Steroid resistant gut aGvHD is defined as cases in which gastrointestinal symptoms do not improve within 7 days after initial steroid therapy (≥1 mg/kg of methylprednisolone) or clear progression after 5 days.)
  • Steroid-dependent gut aGVHD is defined as cases in which reduction of steroid dose was not possible due to exacerbation of gastrointestinal symptoms.
  • Participants may have undergone allogeneic HSCT for any diagnosis at any time prior to developing aGvHD, and are not restricted to any specific conditioning regimen or by the subsequent administration of donor lymphocyte infusion.
  • Participants should be able to give informed consent.

Exclusion Criteria:

  • Participants may not have gut aGvHD which permits the tapering of steroid dose.
  • Participants may not have ongoing, uncontrolled infection (i.e. unresolved bacteremia, uncontrolled CMV infection).
  • Participants may not have ongoing enteritis primarily caused by enteropathy other than gut GvHD, excluding resistant clostridium difficile infection.
  • Participants may not have acute neutrophil count < 500 cells/µL.
  • Participants may not have toxic megacolon
  • Participants may not have active gastrointestinal bleeding.
  • Participants may not be pregnant or lactating.
  • Participants may not be unable to swallow pills.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03214289


Contacts
Layout table for location contacts
Contact: Roni Shouval, MD 972-3-5305830 roni.shoval@sheba.health.gov.il

Locations
Layout table for location information
Israel
Chaim Sheba Medical Center Recruiting
Ramat Gan, Israel
Sponsors and Collaborators
Sheba Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Roni Shouval, MD Sheba Medical Center

Layout table for additonal information
Responsible Party: Dr. Shouval Roni, Principal Investigator, Hematology and BMT Division, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT03214289     History of Changes
Other Study ID Numbers: 3822-16-SMC
3822-16-SMC ( Other Identifier: Sheba Medical Center, Tel-HaShomer, Israel )
First Posted: July 11, 2017    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Shouval Roni, Sheba Medical Center:
Fecal Microbiota Transplantation
Intestinal Acute Graft Versus Host Disease
Hematopoietic Stem Cell Transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Acute Disease
Immune System Diseases
Disease Attributes
Pathologic Processes